Login
$TENX
$1.48 +$0.00 (0.0%) After hours

$TENX 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol

08 Oct 2026 8-K: Other Events

Forward-Looking Statements Disclaimers Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. These forward-looking statements include, but ar...

09 Sep 2026 8-K: Regulation FD Disclosure

LEVEL Clinical Trial Results September 09, 2026 Exhibit 99.1

10 Aug 2026 8-K: Other Events

TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk

31 Jul 2026 8-K: Results of Operations and Financial Condition

Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026

02 Jul 2026 8-K: Other Events

Abstract recently submitted in anticipation of initial data analysis ahead of ESC

30 Jun 2026 8-K: Entry into a Material Definitive Agreement

This sixth Amendment to the License Agreement of September 20, 2013 (hereinafter referred to as the “Amendment”) is made and executed as of this 29th day of June, 2026 (“Effective Date of Amendment”) by and between

29 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

THIS FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), is made as of June 29, 2026 by and between Tenax Therapeutics, Inc., a Delaware corporation, with its principal place of business in North Carolina (the “Company”...

04 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 2, 2026, Tenax Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following proposals were voted upon at the Annual Meeting and the final voting results with respect to eac...

12 May 2026 8-K: Results of Operations and Financial Condition

On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026

22 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

This Executive Employment Agreement (this “Agreement”) is made as of April 9, 2026, by and between Tenax Therapeutics, Inc., a Delaware corporation, with its principal place of business in North Carolina (the “Company”), and Thomas R Sta...

10 Mar 2026 8-K: Results of Operations and Financial Condition

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026

09 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

THIS SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), is made as of January 6, 2026 by and between Tenax Therapeutics, Inc., a Delaware corporation, with its principal place of business in North Carolina (the “Compa...

17 Dec 2025 8-K: Other Events

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study

12 Nov 2025 8-K: Results of Operations and Financial Condition

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026

16 Sep 2025 8-K: Other Events

Provides Patent Protection in Europe Through at Least December 2040

09 Sep 2025 8-K: Entry into a Material Definitive Agreement

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].”

13 Aug 2025 8-K: Results of Operations and Financial Condition

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026

17 Jun 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Tenax Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows:

14 May 2025 8-K: Results of Operations and Financial Condition

Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support